ClearPoint Neuro (CLPT) FDA Approvals $17.29 -0.19 (-1.09%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$17.31 +0.02 (+0.12%) As of 07/8/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ClearPoint Neuro's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by ClearPoint Neuro (CLPT). Over the past two years, ClearPoint Neuro has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ClearPoint. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ClearPoint Prism Neuro Laser Therapy System FDA Regulatory Events ClearPoint Prism Neuro Laser Therapy System is a drug developed by ClearPoint Neuro for the following indication: Brain Tumor Laser Therapy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Results - October 7,2025Results Phase 1/2Drug: ClearPoint Prism Neuro Laser Therapy SystemAnnounced Date: October 7, 2025Indication: Brain Tumor Laser TherapyAnnouncementClearPoint Neuro, Inc announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy..AI SummaryClearPoint Neuro, Inc. shared Phase I-II study results from Skåne University Hospital in Lund, Sweden. This trial tested the ClearPoint Prism Neuro Laser Therapy System for safety, feasibility, and effectiveness in 14 patients with primary or recurrent glioblastoma or grade 4 astrocytoma. The findings showed improved survival compared to matched open‐surgery controls, with no device‐related events or complications. The workflow proved safe, feasible, and reproducible, and the median time to ablate each tumor was just 6.5 minutes. Chris Osswald, PhD, said these results show potential for minimally invasive neuro‐oncology treatment. He added that the system’s fast, simple, and predictable workflow can improve patient care and support future cell and gene therapy applications. The ClearPoint Prism Neuro Laser Therapy System will be featured at the 75th Annual Congress of Neurological Surgeons in Los Angeles on October 13–15, 2025.Read Announcement ClearPoint Neuro FDA Events - Frequently Asked Questions Has ClearPoint Neuro received FDA approval? As of now, ClearPoint Neuro (CLPT) has not received any FDA approvals for its therapy in the last two years. What drugs has ClearPoint Neuro submitted to the FDA? In the past two years, ClearPoint Neuro (CLPT) has reported FDA regulatory activity for ClearPoint Prism Neuro Laser Therapy System. What is the most recent FDA event for ClearPoint Neuro? The most recent FDA-related event for ClearPoint Neuro occurred on October 7, 2025, involving ClearPoint Prism Neuro Laser Therapy System. The update was categorized as "Results," with the company reporting: "ClearPoint Neuro, Inc announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy.." What conditions do ClearPoint Neuro's current drugs treat? Currently, ClearPoint Neuro has one therapy (ClearPoint Prism Neuro Laser Therapy System) targeting the following condition: Brain Tumor Laser Therapy. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Arcutis Biotherapeutics FDA EventsUrogen Pharma FDA EventsVaccinex FDA EventsAgios Pharmaceuticals FDA EventsAlterity Therapeutics FDA EventsAxsome Therapeutics FDA EventsCompass Pathways FDA EventsErnexa Therapeutics FDA EventsKymera Therapeutics FDA EventsSAB Biotherapeutics FDA EventsTurn Therapeutics FDA EventsTvardi Therapeutics FDA EventsAgenus FDA EventsAtai Beckley FDA EventsFate Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Pulse Biosciences FDA Events NovoCure FDA Events Inspire Medical Systems FDA Events PROCEPT BioRobotics FDA Events Alpha Tau Medical FDA Events Artivion FDA Events Bioventus FDA Events SS Innovations International FDA Events Tactile Systems Technology FDA Events Spyglass Pharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CLPT last updated on 10/8/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Results - October 7,2025Results Phase 1/2Drug: ClearPoint Prism Neuro Laser Therapy SystemAnnounced Date: October 7, 2025Indication: Brain Tumor Laser TherapyAnnouncementClearPoint Neuro, Inc announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System's safety, feasibility, and efficacy..AI SummaryClearPoint Neuro, Inc. shared Phase I-II study results from Skåne University Hospital in Lund, Sweden. This trial tested the ClearPoint Prism Neuro Laser Therapy System for safety, feasibility, and effectiveness in 14 patients with primary or recurrent glioblastoma or grade 4 astrocytoma. The findings showed improved survival compared to matched open‐surgery controls, with no device‐related events or complications. The workflow proved safe, feasible, and reproducible, and the median time to ablate each tumor was just 6.5 minutes. Chris Osswald, PhD, said these results show potential for minimally invasive neuro‐oncology treatment. He added that the system’s fast, simple, and predictable workflow can improve patient care and support future cell and gene therapy applications. The ClearPoint Prism Neuro Laser Therapy System will be featured at the 75th Annual Congress of Neurological Surgeons in Los Angeles on October 13–15, 2025.Read Announcement
